Cantitate/Preț
Produs

Immunotherapy for Pediatric Malignancies

Editat de Juliet C. Gray, Aurélien Marabelle
en Limba Engleză Hardback – 5 dec 2017
This book provides a comprehensive overview of current immunotherapy strategies, and how these may be applicable to childhood cancers. The first part of the book reviews how the immune system recognizes cancer, and the various escape mechanisms allowing tumour growth. The importance of the tumor microenvironment and the challenges this may present to achieving effective immunotherapy are discussed. Monoclonal antibodies, cellular, cytokine and vaccine therapies are all comprehensively reviewed, with particular focus on their potential application to pediatric cancers. Practical aspects of delivering such therapies to children, likely toxicities and potential biomarkers are considered. Finally, consideration is given to how, in the longer term, such therapies may be combined with conventional therapies such as chemotherapy and radiotherapy.
Edited by two distinguished pediatric oncologists with a collection of chapters from the most authoritative experts in cancer immunotherapy, this is an indispensable volume for pediatric oncologists and physicians working in childhood cancer care.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 74183 lei  39-44 zile
  Springer International Publishing – 27 mai 2018 74183 lei  39-44 zile
Hardback (1) 103451 lei  39-44 zile
  Springer International Publishing – 5 dec 2017 103451 lei  39-44 zile

Preț: 103451 lei

Preț vechi: 108897 lei
-5% Nou

Puncte Express: 1552

Preț estimativ în valută:
19796 20826$ 16433£

Carte tipărită la comandă

Livrare economică 13-18 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319434841
ISBN-10: 3319434845
Pagini: 250
Ilustrații: IX, 297 p. 29 illus., 27 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.65 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland

Cuprins

Introduction to Pediatric Cancer Immunotherapy.- Overcoming immune suppression in the tumor microenvironment: Implications for multi-modal therapy.- Allogeneic stem cell transplantation.- Overview of monoclonal antibody therapies.- Monoclonal Antibodies Targeting Hematological Malignancies.- Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours.- Monoclonal antibodies targeting the immune system.- Adoptive T Cell Therapies for Children’s Cancers.- NK Cell and NKT Cell Immunotherapy.- Cancer Vaccines in Pediatrics.- Immune Adjuvants and Cytokine Therapies.- Immune biomarkers in pediatric malignancies.- Future perspectives

Recenzii

“Addressing the major histological, biological, and developmental differences between children and adult cancer patients, this comprehensive book provides up-to-date, state-of-the-art information on immunotherapy for pediatric malignancies. … The book is intended primarily for pediatric oncologists and physicians, fellows, and interns working in pediatric cancer care. … this is a great book that is very informative and authoritative and includes experiences from clinicians and scientists working at some of the most renowned cancer centers in the world.” (Ravi Salgia, Doody's Book Reviews, August, 2018)

Notă biografică

Dr. Juliet Gray is an Associate Professor and Consultant in Paediatric Oncology at the University of Southampton, UK.  She has a strong clinical and research interest in immunotherapy for neuroblastoma, with particular expertise in novel antibody therapies. She leads a translational laboratory research group within the Southampton Cancer Immunology Centre, and is an active member of the UK NCRI Neuroblastoma group and SIOP European Neuroblastoma Research Network (SIOPEN).
Aurélien Marabelle, is currently the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. Dr Marabelle is an immunologist and a pediatric oncologist by training. His clinical practice is currently dedicated to Early Phase Clinical trials in Cancer Immunotherapy and his translational research is focused on mechanisms of action of immune targeted therapies. He works as a senior medical oncologist and an investigator in the Drug Development Department (DITEP) directed by Prof Jean-Charles Soria. He is coordinating a team focusing on cancer immunotherapy translational research projects in the INSERM U1015 lab directed by Prof Laurence Zitvogel. Dr Marabelle is a member of the European Society of Medical Oncology (ESMO), the American Association of Clinical Oncology (ASCO), the European Academy of Tumor Immunology (EATI) & the American Association of Cancer Research (AACR).

Textul de pe ultima copertă

This book provides a comprehensive overview of current immunotherapy strategies, and how these may be applicable to childhood cancers. The first part of the book reviews how the immune system recognizes cancer, and the various escape mechanisms allowing tumour growth. The importance of the tumor microenvironment and the challenges this may present to achieving effective immunotherapy are discussed. Monoclonal antibodies, cellular, cytokine and vaccine therapies are all comprehensively reviewed, with particular focus on their potential application to pediatric cancers. Practical aspects of delivering such therapies to children, likely toxicities and potential biomarkers are considered. Finally, consideration is given to how, in the longer term, such therapies may be combined with conventional therapies such as chemotherapy and radiotherapy.
Edited by two distinguished pediatric oncologists with a collection of chapters from the most authoritative experts in cancer immunotherapy, this is an indispensable volume for pediatric oncologists and physicians working in childhood cancer care.

Caracteristici

Comprehensively reviews immunotherapy strategies currently used in the treatment of cancer and how these are applicable to pediatric malignancies Addresses key issues, such as immune-related toxicities, and practical challenges for delivery in the pediatric population Discusses how current therapies may be optimized and improved, and how they may be incorporated into existing treatment regimens Includes supplementary material: sn.pub/extras